Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards

Novartis Launches COPD Inhalation Capsules in Japan

By Drug Discovery Trends Editor | November 21, 2013

Sosei Group Corp. confirms that Novartis Pharma K.K. launched once-daily Ultibro Inhalation Capsules (“Ultibro”; glycopyrronium/indacaterol), for relief of various symptoms due to airway obstruction in chronic obstructive pulmonary disease (COPD). Ultibro was developed by Novartis under the name of QVA149. 
 
Dual bronchodilation with Ultibro is expected to set a new standard of care in COPD by combining the proven efficacy benefits and safety profiles of two established Novartis COPD treatments, the LABA, Onbrez Inhalation Capsules (indacaterol), and the LAMA, Seebri Inhalation Capsules (glycopyrronium bromide).
 
All Novartis inhaled COPD portfolio products are developed for delivery via a single-dose dry powder inhaler (SDDPI) called the Breezhaler inhalation device which has low air flow resistance, making it suitable for patients with airflow limitation. The Breezhaler device allows patients to hear, feel and see that they have taken the full dose correctly. 
 
Ultibro was approved in Japan and EU (under the brand name Ultibro Breezhaler) in September, and has since been launched in Germany and Netherlands. U.S. submission is anticipated in the second half of 2014. 
  
Seebri, Onbrez and Breezhaler are registered trademarks of Novartis AG. 
 
Date: November 20, 2013
Source: Sosei Group Corp.
 

Related Articles Read More >

AltImmune
Intranasal COVID-19 vaccines could be on the horizon
COVID-19 coronavirus
NIH starts Phase 3 trial of blood clotting treatments for COVID-19
Merck logo
Merck moving to Phase 2 study of drug-eluting implant to prevent HIV infection
AstraZeneca-Oxford
Study finds AstraZeneca COVID-19 vaccine could be effective against Brazil variant

DeviceTalks Tuesdays

DeviceTalks Tuesdays

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup

R&D Twitter

Tweets by @RandDWorld
Drug Discovery and Development
  • Enews Signup
  • Contact Us
  • R&D World
  • Pharmaceutical Processing
  • Drug Delivery Business News

Copyright © 2021 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Orphan Drugs
  • R&D 100 Awards